STOCK TITAN

Tango Therapeutics: Farallon reports 4.9% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Tango Therapeutics, Inc. (TNGX) is the issuer in an amended ownership report by Farallon Capital Management, L.L.C., identified as investment manager, and its listed managing-member or senior-managing-member reporting persons: Joshua J. Dapice, Philip D. Dreyfuss, Hannah E. Dunn, Varun N. Gehani, Nicolas Giauque, Avner A. Husen, David T. Kim, Michael G. Linn, Patrick (Cheng) Luo, Thomas G. Roberts, Jr., Edric C. Saito, Daniel S. Short, Andrew J. M. Spokes, John R. Warren and Mark C. Wehrly. Each reports the same 8,543,875 shares of shared beneficial ownership, or 4.9% of the class, as of September 30, 2026. The Farallon Funds directly hold 4,550,688 common shares and 3,993,187 pre-funded warrants, each exercisable for one share; the reported amount assumes all warrants are exercisable within 60 days.

Reported beneficial ownership 8,543,875 shares Each reporting person reports this shared amount as of September 30, 2026.
Ownership percentage 4.9% Percentage of the class reported by each reporting person.
Common shares held 4,550,688 shares Shares held directly by the Farallon Funds as of September 30, 2026.
Pre-funded warrants 3,993,187 warrants Each warrant is exercisable for one share, subject to the Beneficial Ownership Limitation.
Beneficial Ownership Limitation 9.99% The limit did not prevent exercise of any warrants as of September 30, 2026.
Pre-Funded Common Stock Purchase Warrants technical
"3,993,187 Pre-Funded Common Stock Purchase Warrants"
A pre-funded common stock purchase warrant is a contract that gives an investor the right to receive a company’s common shares later after having paid nearly the full share price up front, leaving only a very small remaining payment to convert the warrant into an actual share. Think of it like reserving a product by paying almost everything now and paying a tiny balance later; it provides immediate capital to the company, limits immediate dilution of outstanding shares, and lets investors manage ownership limits and timing of when they actually hold tradable stock.
Beneficial Ownership Limitation regulatory
"more than 9.99% of the Shares then issued and outstanding"
A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much TNGX does Farallon report beneficially owning?

The reporting persons each report 8,543,875 shares, or 4.9% of Tango Therapeutics' common stock, as of September 30, 2026. The amount is reported with shared voting and dispositive power and reflects the same position across the reporting persons.

What limits exercise of Farallon's TNGX warrants?

The warrants may not be exercised if the exercise would cause the reporting persons to beneficially own more than 9.99% of the shares then issued and outstanding. As of September 30, 2026, that limit did not prevent exercise of any warrants. The report assumes all 3,993,187 warrants are exercisable within 60 days.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





87583X109

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Farallon Capital Management, L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Managing Member
Date:11/16/2026
Dapice Joshua J.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:11/16/2026
Dreyfuss, Philip D.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:11/16/2026
Dunn Hannah E.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn
Date:11/16/2026
Gehani, Varun N.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:11/16/2026
Giauque, Nicolas
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:11/16/2026
Husen, Avner A.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:11/16/2026
Kim, David T.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:11/16/2026
Linn, Michael G.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:11/16/2026
Luo Patrick (Cheng)
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:11/16/2026
Roberts, Jr., Thomas G.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:11/16/2026
Saito Edric C.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:11/16/2026
Short Daniel S.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:11/16/2026
Spokes, Andrew J. M.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:11/16/2026
Warren, John R.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:11/16/2026
Wehrly, Mark C.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:11/16/2026

Keep reading